Apremilast Efficacy Results Disappoint But May Be Enough For Commercial Success

Celgene’s PDE-4 inhibitor met the primary endpoint in the first of two pivotal Phase III trials, but analysts worried that the treatment effect was less than that seen in a Phase II study. Some analysts still see a strong niche position for apremilast in treatment-naïve patients before they move on to biologic therapy.